
|Articles|July 24, 2015
Cogstate Releases Online Cognitive Screening Solution for Alzheimer's Trial
This new version release optimizes patient recruitment with study-specific prescreening workflows and a delivery platform that allows for self-administered cognitive assessments on any modality including tablet-based assessments
Advertisement
Cogstate, a cognitive science and medical technology company, announced the latest version of its remote cognitive assessment solution for pre-screening participants in clinical trials, Precision Recruitment™ 2.1.
This new version release optimizes patient recruitment with study-specific prescreening workflows and a delivery platform that allows for self-administered cognitive assessments on any modality including tablet-based assessments. Other important new features include:
- Functionality allowing pre-screened participants to select an investigator site in their area, with automatic site notification for a more seamless enrolment process.
- The ability to deploy the solution in many different languages, as required for global clinical trials
Advertisement
Related to this article

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, outlines how integrating trial matching with standard of care workflows and uniform screening can replace reliance on physician memory with timely, consistent nudges.

Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, makes the case that oncologists must lead discussions about randomization and treatment decisions, while AI can prepare patients beforehand and support them afterward.

In today’s ACT Brief, we examine how AI can cut coordinator screening time, how participants respond to AI-assisted pre-screening, and how FDA approved three new treatments.

Participants in a survey of 354 pre-screening respondents rated AI voice-assisted screening (Clara) favorably and were more likely to schedule and attend study appointments than web-form users, though self-selection means the association cannot be read as causal.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, explains how AI can unlock unstructured chart data and cut coordinator screening time from hours to minutes, easing a clinical research workforce under strain.

In today’s ACT Brief, we examine what drives inconsistent oncology trial screening, why FDA has reportedly paused its priority voucher pilot, and how patients’ use of AI is reshaping how sponsors communicate with them.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where AI Helps in Patient Conversations About Trials and Where Humans Must Lead
2
Participant Experience with AI-Assisted and Web-Based Clinical Trial Pre-Screening
3
ACT Brief: AI-Driven Coordinator Screening, Participant Pre-Screening Perceptions, and Three New FDA Approvals
4
Measuring Burden Before It Becomes Risk: Coordinator Friction, Tool Fatigue, and Trial Quality
5

